ChargePoint Acquires Assets of Forac
ChargePoint Technology announced that it has acquired the assets of Forac Limited.
ChargePoint Technology, a UK-based manufacturer and supplier of precision containment valves to the pharmaceutical and chemical industries, announced that it has acquired the assets of Forac Limited, a key business in its supply chain.
Under the deal, ChargePoint will have access to a compact pneumatic actuator used to open and close the isolation valves that feature in production processes used by the pharmaceutical, food and fuel industries. No financial terms were disclosed.
Forac will relocate its plant and stock from a base in Shoreham-by-Sea, West Sussex to ChargePoint’s manufacturing plant in Speke, Merseyside. Founder and managing director of Forac Adam Bunyard has joined ChargePoint as part of the deal.
ChargePoint’s containment valves are used for the safe and sterile handling of powders in manufacturing processes, for example when making drugs in tablet form. The valves enable safe transferring of powders from one vessel to another during the production process. By minimizing dust emissions, they are specified to prevent cross-contamination and protect operators from exposure to potent substances.
Source: ChargePoint
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
